No record found
No record found
capitalstake.com. Provided by * Returns not adjusted for payouts
^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.
Company Profile
GlaxoSmithKline Pakistan Limited is incorporated in Pakistan as a limited liability company. It is engaged in manufacturing and marketing of research based ethical specialties and pharmaceutical products. The Company is a subsidiary of S.R. One International B.V., incorporated in Netherlands, whereas its ultimate parent company is GlaxoSmithKline plc, UK (GSK plc).
| Erum Shakir Rahim | CEO |
| Hina Mir | Company Secretary |
CDC Share Registrar Services Limited CDC House, 99 - B, Block - B S.M.C.H.S., Main Shahra-e-Faisal Karachi
Yousuf Adil, Chartered Accountants
December
Equity Profile
Announcements
| Date | Title | Document |
|---|---|---|
| Mar 26, 2026 | Financial Results for the year Ended 2025-12-31 | View PDF |
| Oct 29, 2025 | Transmission of Quarterly Report for the period ended September 30, 2025 | View PDF |
| Oct 24, 2025 | Financial Results for the Quarter ended September 30, 2025 | View PDF |
| Aug 29, 2025 | Transmission of Half Yearly Report for the Period ended June 30, 2025 | View PDF |
| Aug 26, 2025 | Financial Results for the Quarter ended June 30, 2025 | View PDF |
| Date | Title | Document |
|---|---|---|
| Mar 18, 2026 | Board Meeting Quarter 4, 2025 | View PDF |
| Oct 16, 2025 | Notice of Board of Directors Meeting (Q3-2025) | View PDF |
| Aug 19, 2025 | Notice of Board of Directors Meeting (Q2- 2025) | View PDF |
| Apr 28, 2025 | Certified True Copy of the Resolutions passed by shareholders in the Annual General Meeting held on April 28, 2025 | View PDF |
| Apr 17, 2025 | Board Meeting Quarter ended March 31, 2025 | View PDF |
| Date | Title | Document |
|---|---|---|
| Mar 31, 2026 | Material Information | View PDF |
| Dec 5, 2025 | Presentation for Corporate Briefing Session -2025 | View PDF |
| Dec 3, 2025 | Notice of Corporate Briefing Session - 2025 | View PDF |
| Sep 19, 2025 | Credit of Interim cash dividend | View PDF |
| Sep 2, 2025 | Notice of interim cash dividend and share book closure | View PDF |
Financials
All numbers in thousands (000's) except EPS
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 65,900,901 | 61,187,501 | 49,661,277 | 41,841,585 |
| Profit after Taxation | 10,025,315 | 6,536,047 | 533,953 | 2,462,892 |
| EPS | 31.48 | 20.52 | 1.68 | 7.73 |
| Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | |
|---|---|---|---|---|
| Sales | 14,188,008 | 14,720,667 | 15,580,140 | 14,730,940 |
| Profit after Taxation | 2,037,285 | 2,068,811 | 2,126,547 | 1,927,134 |
| EPS | 6.40 | 6.50 | 6.68 | 6.05 |

Ratios
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Gross Profit Margin (%) | 37.00 | 25.15 | 7.05 | 17.40 |
| Net Profit Margin (%) | 15.21 | 10.68 | 1.08 | 5.89 |
| EPS Growth (%) | 53.41 | 1,121.43 | (78.27) | (54.02) |
| PEG | 0.23 | 0.02 | (0.63) | (0.21) |










Feedback
Terms of Use
https://www.psx.com.pk